Coya Therapeutics Secures Key Therapy License

Clinical-stage biotech company Coya Therapeutics expands its IP portfolio with a license for a novel combination therapy using low dose interleukin-2 and GM-CSF. The therapy shows promising results in preclinical studies, increasing regulatory T cell function. This expands Coya's therapeutic pipeline and potential treatment options, particularly for inflammatory disorders and neurodegenerative diseases. However, the products are investigational and awaiting regulatory approval.